Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CAV3 gene in treatment of diabetic cardiomyopathy

A technology for diabetic cardiomyopathy and diabetes, applied in gene therapy, pharmaceutical formula, metabolic diseases, etc.

Pending Publication Date: 2020-04-10
GUANGXI MEDICAL UNIVERSITY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no evidence that increasing CAV3 protein in cardiac muscle and vascular smooth muscle cells can improve diabetic cardiomyopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CAV3 gene in treatment of diabetic cardiomyopathy
  • Application of CAV3 gene in treatment of diabetic cardiomyopathy
  • Application of CAV3 gene in treatment of diabetic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0038] 1. Experimental content

[0039] 1.1 Experimental animals

[0040] Healthy ♂ SD rats, SPF grade, 4 weeks old, body weight (180±20) g, were purchased from the Experimental Animal Center of Guangxi Medical University [SYXK (Gui) 2014-0003]. The experimental operation was carried out in the imaging operation room of the animal center. The animal experiments were approved by the Experimental Animal Management Committee (201710012). The use of experimental animals was given humane care in accordance with the 3R principle.

[0041] 1.2 Drugs and reagents

[0042] Streptozotocin (streptozotocin, STZ) and sodium pentobarbital were purchased from Sigma Corporation of the United States; citric acid and trisodium citrate were products of Beijing Suolaibao Technology Co., Ltd.; blood glucose test strips (Johnson & Johnson China Medical Equipment Co., Ltd.); Lactate dehydrogenase assay kit, creatine kinase assay kit, superoxide dismutase assay kit and malondialdehyde assay kit wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The inventors found through in-depth research that diabetic rats are accompanied by cardiomyopathy and during the occurrence and development of the disease course, CAV3 increases first and then decreases slowly, especially the decrease of cardiac CAV3 protein in the middle and late stages suggests that early injury is accompanied by the increase of CAV3 compensation and the decrease of CAV3 in themiddle and late stages is accompanied by the decompensation of cardiac insufficiency. Accordingly, by adenovirus or liposome or any transgenic means, or direct injection of CAV3 protein or peptide chain with the same functional domain, or other means to increase CAV3 protein in myocardial cells and cardiovascular smooth muscle cells, the purpose of improving myocardial metabolism, structure and function can be achieved, and even patients completely recover to normal. Therefore, the CAV3 gene and its protein have great potential in the treatment of diabetic cardiomyopathy, and can be used forthe treatment of diabetic patients with myocardial structural and functional changes. By restoring the physiological function of DCM myocardial CAV3 through transgene, the myocardial metabolism, structure and function of DCM are improved, and effective treatment of DCM is realized.

Description

technical field [0001] The invention relates to diabetic cardiomyopathy, in particular to the application of CAV3 gene in treating diabetic cardiomyopathy. Background technique [0002] Diabetes has become a global human health problem. The latest American Society of Cardiology / American Heart Association / American Heart Failure Society heart failure guidelines point out that more than 29 million adults in the United States currently suffer from T2DM (type 2 diabetes), Of these, 6.5 million have heart failure (HF) and are expected to continue to increase. These two chronic diseases with high morbidity and mortality lead to a severe deterioration of patients' quality of life. It is estimated that nearly 500 million people will suffer from DM by 2030, and the main complication of DM is cardiovascular disease, which accounts for more than two-thirds of diabetes morbidity and mortality. Among them, diabetic patients may experience damage to myocardial metabolism, structure and f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61P3/10A61P9/00
CPCA61K48/005A61P3/10A61P9/00
Inventor 黄勤
Owner GUANGXI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com